Tsurutani J - Search Results

1

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.

Nishihara S, Yamaoka T, Ishikawa F, Ohmori T, Ando K, Kusumoto S, Kishino Y, Manabe R, Hasebe Y, Sagara H, Yoshida H, Tsurutani J. Nishihara S, et al. Among authors: tsurutani j. Cells. 2022 Jul 14;11(14):2201. doi: 10.3390/cells11142201. Cells. 2022. PMID: 35883645 Free PMC article.

2

KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.

Nakatani K, Yamaoka T, Ohba M, Fujita KI, Arata S, Kusumoto S, Taki-Takemoto I, Kamei D, Iwai S, Tsurutani J, Ohmori T. Nakatani K, et al. Among authors: tsurutani j. Mol Cancer Ther. 2019 Jan;18(1):112-126. doi: 10.1158/1535-7163.MCT-18-0591. Epub 2018 Oct 15. Mol Cancer Ther. 2019. PMID: 30322949

3

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.

Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K. Watanabe S, et al. Among authors: tsurutani j. Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27. Cancer Sci. 2019. PMID: 30390416 Free PMC article.

4

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.

Yamaoka T, Ohba M, Matsunaga Y, Tsurutani J, Ohmori T. Yamaoka T, et al. Among authors: tsurutani j. J Vis Exp. 2019 Jun 26;(148). doi: 10.3791/59473. J Vis Exp. 2019. PMID: 31305510

5

Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.

Yamaoka T, Arata S, Homma M, Homma T, Kusumoto S, Ando K, Manabe R, Kishino Y, Ohba M, Tsurutani J, Takimoto M, Ohmori T, Sagara H. Yamaoka T, et al. Among authors: tsurutani j. Int J Mol Sci. 2019 Aug 17;20(16):4021. doi: 10.3390/ijms20164021. Int J Mol Sci. 2019. PMID: 31426531 Free PMC article.

6

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Yoshioka H, et al. Among authors: tsurutani j. Ann Oncol. 2019 Dec 1;30(12):1978-1984. doi: 10.1093/annonc/mdz399. Ann Oncol. 2019. PMID: 31553438 Free article. Clinical Trial.

7

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.

Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: tsurutani j. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.

8

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.

Yamaoka T, Tsurutani J, Sagara H, Ohmori T. Yamaoka T, et al. Among authors: tsurutani j. Transl Lung Cancer Res. 2020 Oct;9(5):2178-2183. doi: 10.21037/tlcr-20-578. Transl Lung Cancer Res. 2020. PMID: 33209639 Free PMC article. No abstract available.

9

Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells.

Matsunaga Y, Yamaoka T, Ohba M, Miura S, Masuda H, Sangai T, Takimoto M, Nakamura S, Tsurutani J. Matsunaga Y, et al. Among authors: tsurutani j. Antibodies (Basel). 2021 Feb 1;10(1):6. doi: 10.3390/antib10010006. Antibodies (Basel). 2021. PMID: 33535554 Free PMC article.

10

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer.

Nishihara S, Yamaoka T, Ishikawa F, Higuchi K, Hasebe Y, Manabe R, Kishino Y, Kusumoto S, Ando K, Kuroda Y, Ohmori T, Sagara H, Yoshida H, Tsurutani J. Nishihara S, et al. Among authors: tsurutani j. Genes (Basel). 2022 Nov 22;13(12):2183. doi: 10.3390/genes13122183. Genes (Basel). 2022. PMID: 36553449 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page